NYSE: BIOBio Rad Laboratories Inc Stock
$369.95+6.45 (+1.77%)
Updated Oct 23, 2026
BIO Price
$369.95
Fair Value Price
N/A
Market Cap
$9.89B
52 Week Low
$236.73
52 Week High
$396.23
P/E
45.96x
P/B
1.38x
P/S
3.03x
PEG
3.43x
Dividend Yield
N/A
Revenue
$2.59B
Earnings
$222.40M
Gross Margin
51.9%
Operating Margin
15.42%
Profit Margin
8.6%
Debt to Equity
0.43
Operating Cash Flow
$493M
Beta
0.95
Next Earnings
Nov 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BIO Overview
Bio-Rad Laboratories, Inc. develops and manufactures specialized technological products for the life science research and clinical diagnostics markets. Offerings include instruments, software, consumables, reagents, and content for cell biology, gene expression, and protein purification. It also offers diagnostic products and systems used in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. The company was founded in 1952 and is based in Hercules, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BIO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important BIO news, forecast changes, insider trades & much more!
BIO News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIO ($369.95) is trading above its intrinsic value of $70.47, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BIO is good value based on its earnings relative to its share price (45.96x), compared to the US market average (46.06x)
P/E vs Market Valuation
BIO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BIO due diligence checks available for Premium users.
Valuation
BIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
45.96x
Industry
22.76x
Market
46.06x
BIO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BIO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
BIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.38x
Industry
3.18x
BIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIO price to earnings growth (PEG)
For valuing profitable companies with growth potential
BIO is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
BIO's financial health
Profit margin
Revenue
$651.0M
Net Income
$371.4M
Profit Margin
57.1%
BIO's Earnings (EBIT) of $399.20M... subscribe to Premium to read more.
Interest Coverage Financials
BIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.3B
Liabilities
$3.1B
Debt to equity
0.43
BIO's short-term assets ($3.02B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIO's short-term assets ($3.02B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$98.7M
Investing
-$66.7M
Financing
-$27.6M
BIO's operating cash flow ($492.60M)... subscribe to Premium to read more.
Debt Coverage Financials
BIO vs Medical Device Stocks
Bio Rad Laboratories Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.